|Day Low/High||2.27 / 2.43|
|52 Wk Low/High||1.57 / 3.20|
SAN DIEGO and TORONTO, July 23, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc.
- CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML - - APTO-253 MYC inhibitor being developed for the treatment of AML and MDS - SAN DIEGO and TORONTO, July 16,...
Conference Call and Webcast at 5pm EDT Today
CG'806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples
Data elucidate unique ability of CG'806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents
Conference Call and Webcast at 5pm EST Today
Aptose Provides Corporate Update Highlights
Data support superiority of CG'806 relative to competitive agents against AML driven by diverse mutated forms of FLT3
Data support superiority of CG'806 relative to select competitive agents
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.